A DSE banking stock trades at Tk 22 per share. Its book value is Tk 34. That is a 35% discount to the assets on its balance sheet — and yet the stock has gone nowhere for two years.
Down the board, a pharmaceutical company trades at Tk 480 with a book value of Tk 95. Investors are paying five times the net assets and the stock keeps climbing.
One looks cheap. The other looks expensive. The price to book ratio explains why both prices might be exactly right — and why confusing the two can cost you real money.
What the P/B Ratio Actually Measures
The formula is straightforward:
P/B Ratio = Market Price per Share / Book Value per Share
Book value per share is the company’s total assets minus total liabilities, divided by the number of outstanding shares. It represents what shareholders would theoretically receive if the company liquidated everything today.
A P/B below 1.0 means the market values the company at less than its net assets. Around 1.0 means the stock trades roughly at asset value. Above 3.0 means investors are paying a significant premium — betting that the company’s earning power, brand, or growth potential far exceeds what the balance sheet shows.
But the number alone tells you almost nothing. A P/B of 0.6 in the banking sector means something entirely different from a P/B of 0.6 in pharmaceuticals. The sector context is where the ratio becomes useful — and where most investors on the DSE get it wrong.
Why DSE Banks Often Trade Below Book Value
The financial sector globally averages a P/B between 1.5 and 2.0. On the DSE, many banking stocks trade well below that — some below 1.0.
This is not necessarily a buying opportunity. It reflects specific risks that the balance sheet obscures.
Non-performing loans are the primary concern. When a bank reports Tk 100 crore in loan assets, the market asks: how much of that is actually collectible? NPL ratios in parts of the Bangladeshi banking sector have historically run higher than regional peers, which means the “book value” on the balance sheet overstates the real value of those assets. Investors discount accordingly.
Regulatory capital requirements add another layer. Banks must maintain capital adequacy buffers under Bangladesh Bank guidelines. When a bank’s return on equity falls below its cost of capital, it destroys shareholder value with every quarter it operates — and the market prices that destruction in advance.
The DSE banking sector P/E sat at approximately 6.28 in October 2025. When both P/B and P/E are depressed simultaneously, the market is not confused. It is pricing in structural concerns that the headline numbers do not capture.
Why Pharma Trades at a Premium
The DSE pharmaceutical sector tells the opposite story. P/B ratios of 4.0 to 5.5 are common in healthcare globally, and DSE pharma names often command similar premiums.
The reason is what the balance sheet cannot show you.
A pharma company’s most valuable assets — manufacturing approvals, regulatory compliance infrastructure, proprietary formulations, established distribution networks — do not appear at market value on the balance sheet. They are recorded at historical cost or not at all. The gap between what the balance sheet says and what the business is actually worth gets wider every year the company operates.
On the DSE specifically, pharmaceutical manufacturers carry additional value in their export certifications and WHO prequalifications. These are regulatory moats that take years and significant capital to build but show up as modest line items in the accounts.
When investors pay Tk 5 for every Tk 1 of book value in a pharma stock, they are not overpaying. They are pricing in assets that the accounting standards refuse to recognize at fair value.
Bargain or Value Trap: The Only Question That Matters
A low P/B ratio on the DSE creates a fork in the road. One path leads to a genuine bargain. The other leads to dead capital.
Signals of a real bargain: strong ROE despite the low multiple, temporary sector headwinds rather than structural decline, consistent dividend history, solid cash flow, and management with a clear plan to unlock value. The stock is cheap because the market is overreacting to short-term noise.
Signals of a value trap: P/B has been below 1.0 for years with no catalyst in sight, earnings per share are declining or negative, debt is rising relative to equity, and no institutional investors are accumulating. The stock is cheap because the market is right.
The critical test: is the company’s ROE above or below its cost of equity? If ROE consistently trails the cost of capital, the company is worth less than its book value by definition. A P/B below 1.0 in that scenario is not a discount — it is accurate pricing.
When P/B Fails You Entirely
The ratio breaks down for asset-light businesses. Technology companies, service firms, and any business where value lives in intellectual property rather than physical assets will show meaninglessly high P/B ratios. For those, P/E and cash flow analysis are better starting points.
Even for asset-heavy sectors, P/B works best as part of a framework — never in isolation. Combine it with P/E to check earnings quality, ROE to verify the company earns above its cost of capital, and NAV for a second opinion on asset valuation.
The DSE’s overall P/E of 10.1 as of February 2026 suggests the broader market is not expensive by historical standards. But that average masks enormous dispersion between sectors. The investors who use P/B correctly — sector-adjusted, combined with profitability metrics, applied with skepticism about what book value actually represents — are the ones who find the genuine bargains hiding inside that average.
The bank trading at 35% below book might be the opportunity of the year. It might also be priced exactly where it belongs. The P/B ratio gives you the question. Everything else in your toolkit gives you the answer.
Disclaimer: This article is for educational purposes only and does not constitute investment advice. Consult a BSEC-licensed investment adviser before making any investment decisions.